FDA Guidance — Minimal Manipulation (21 CFR Part 1271)

The concept of minimal manipulation is a central regulatory criterion used to determine whether a human cell or tissue product may qualify for regulation solely under Section 361 of the Public Health Service Act and 21 CFR Part 1271.

The U.S. Food and Drug Administration (FDA) has issued guidance documents interpreting how minimal manipulation standards apply to tissues and cellular materials regulated as Human Cells, Tissues, and Cellular and Tissue-Based Products (HCT/Ps).

These guidance materials help manufacturers, tissue establishments, compliance professionals, and healthcare institutions understand how processing steps may affect regulatory classification.

Educational infographic explaining FDA regulatory interpretation of minimal manipulation under 21 CFR 1271.3(f) including structural tissue versus cellular tissue regulatory standards — Educational diagram summarizing how minimal manipulation is interpreted within the regulatory framework governing Human Cells, Tissues, and Cellular and Tissue-Based Products (HCT/Ps) under 21 CFR Part 1271.

Regulatory Definition of Minimal Manipulation

Minimal manipulation is defined in 21 CFR 1271.3(f). The definition is applied differently depending on whether the product is categorized as structural tissue or cells / non-structural tissue.

Structural Tissue

Processing must not alter the original relevant characteristics of the tissue relating to its utility for reconstruction, repair, or replacement.

Cells or Non-Structural Tissue

Processing must not alter the relevant biological characteristics of the cells or tissues.

Further discussion of these distinctions is provided in the page addressing structural tissue versus cellular tissue classification .

Role of FDA Guidance Documents

FDA guidance documents provide interpretive clarification regarding how minimal manipulation standards are applied during regulatory review. These documents outline regulatory reasoning and provide examples of processing methods that may alter relevant tissue characteristics.

Examples frequently discussed within FDA guidance include:

Mechanical processing or shaping of structural tissue
Decellularization methods
Grinding or sizing procedures
Cryopreservation and storage techniques
Isolation, expansion, or culture of cellular components

Interpretation of minimal manipulation is typically evaluated alongside homologous use requirements and other criteria outlined in 21 CFR 1271.10(a).

Relationship to Section 361 Regulatory Qualification

Minimal manipulation is one of four regulatory criteria used to determine whether a product may qualify for regulation under Section 361 rather than the biologics licensing pathway defined under Section 351.

Additional regulatory criteria include:

Homologous use
Non-combination with other active agents
Limited systemic effect or metabolic activity

These regulatory distinctions are discussed further in the overview of Section 361 versus Section 351 classification .

Importance for Regulatory Compliance

Manufacturers, tissue establishments, and healthcare institutions reviewing biologic materials commonly examine processing documentation to determine whether tissue characteristics remain consistent with minimal manipulation standards.

Regulatory review may include examination of:

Processing and manufacturing protocols
Laboratory validation documentation
Manufacturing batch records
Tissue characterization and analytical data

These evaluations typically occur alongside review of donor eligibility determination requirements and current good tissue practice (cGTP) safeguards .

Educational Purpose of This Resource

This page provides educational information summarizing FDA guidance related to minimal manipulation standards within the regulatory framework governing Human Cells, Tissues, and Cellular and Tissue-Based Products.

Additional regulatory education materials are available within the Regulatory Resource Library .